PharmaCyte Biotech, Inc.
PMCB
$0.94
$0.044.34%
NASDAQ
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.75M | 3.52M | 3.94M | 4.10M | 5.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.23M | 3.96M | 4.38M | 4.50M | 5.41M |
| Operating Income | -4.23M | -3.96M | -4.38M | -4.50M | -5.41M |
| Income Before Tax | -7.07M | -1.13M | 30.66M | 20.25M | 22.68M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.07 | -1.13 | 30.66 | 20.25 | 22.68 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.07M | -1.13M | 30.66M | 20.25M | 22.68M |
| EBIT | -4.23M | -3.96M | -4.38M | -4.50M | -5.41M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.32 | -0.47 | 2.94 | 1.05 | 0.84 |
| Normalized Basic EPS | -0.97 | -0.09 | 0.52 | 0.86 | 0.54 |
| EPS Diluted | -1.32 | -0.47 | 2.94 | 1.05 | 0.84 |
| Normalized Diluted EPS | -0.97 | -0.09 | 0.52 | 0.86 | 0.54 |
| Average Basic Shares Outstanding | 27.41M | 28.25M | 29.32M | 30.81M | 32.46M |
| Average Diluted Shares Outstanding | 27.41M | 28.25M | 29.32M | 30.81M | 32.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -0.87% | -- | -- | -- | -- |